The European Commission has granted orphan drug status to JR-446, a brain-penetrating enzyme replacement therapy (ERT) for Sanfilippo syndrome…
Articles by Andrea Lobo
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to JR-446, JCR Pharmaceuticals’ brain-penetrating experimental enzyme…
JCR Pharmaceuticals said it received permission from the Pharmaceuticals and Medical Devices Agency (PMDA), a regulatory agency in Japan,…
An experimental enzyme replacement therapy (ERT), called JR-441, for Sanfilippo syndrome type A has been designated an orphan drug…